(Q51031723)

27 March 2018

title

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. (English)

1 reference

27 March 2018

1 reference

2

1 reference

27 March 2018

Bernard A Fox

5

object named as

Bernard Fox

1 reference

27 March 2018

John Nemunaitis

1

object named as

John Nemunaitis

1 reference

27 March 2018

author name string

David Jablons

3

1 reference

27 March 2018

John W Smith

4

1 reference

27 March 2018

Phil Maples

6

1 reference

27 March 2018

Scott Hamilton

7

1 reference

27 March 2018

Flavia Borellini

8

1 reference

27 March 2018

Andy Lin

9

1 reference

27 March 2018

Sayeh Morali

10

1 reference

27 March 2018

Kristen Hege

11

1 reference

27 March 2018

language of work or name

English

0 references

publication date

1 February 2004

1 reference

27 March 2018

Journal of the National Cancer Institute

published in

1 reference

27 March 2018

volume

96

1 reference

27 March 2018

page(s)

326-331

1 reference

27 March 2018

issue

4

1 reference

27 March 2018

Autologous x-irradiated tumour cells and percutaneous BCG in operable lung cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Failure of specific active immunotherapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH028

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJH028

1 reference

27 March 2018

PubMed ID

14970281

1 reference

27 March 2018